Which Antibody Can Cross BBB? Investigating Engineered Therapies for CNS Disorders
•
3 min read
Only about 0.1% of a standard monoclonal antibody can passively cross the blood-brain barrier (BBB) due to its size and polarity. This biological obstacle poses a significant challenge for delivering treatments to the central nervous system (CNS) and has led researchers to develop innovative solutions to find which antibody can cross BBB effectively.
